CN102428173B - Nk细胞的扩增 - Google Patents

Nk细胞的扩增 Download PDF

Info

Publication number
CN102428173B
CN102428173B CN201080021237.8A CN201080021237A CN102428173B CN 102428173 B CN102428173 B CN 102428173B CN 201080021237 A CN201080021237 A CN 201080021237A CN 102428173 B CN102428173 B CN 102428173B
Authority
CN
China
Prior art keywords
cell
cells
phenotype
sample
expansion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080021237.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102428173A (zh
Inventor
E.阿里西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avaris AB
Original Assignee
Avaris LLC
CellProtect Nordic Pharmaceuticals AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avaris LLC, CellProtect Nordic Pharmaceuticals AB filed Critical Avaris LLC
Publication of CN102428173A publication Critical patent/CN102428173A/zh
Application granted granted Critical
Publication of CN102428173B publication Critical patent/CN102428173B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1164—NK cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CN201080021237.8A 2009-03-26 2010-03-25 Nk细胞的扩增 Active CN102428173B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16359009P 2009-03-26 2009-03-26
US61/163,590 2009-03-26
PCT/SE2010/050333 WO2010110734A1 (en) 2009-03-26 2010-03-25 Expansion of nk cells

Publications (2)

Publication Number Publication Date
CN102428173A CN102428173A (zh) 2012-04-25
CN102428173B true CN102428173B (zh) 2014-07-30

Family

ID=42781254

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080021237.8A Active CN102428173B (zh) 2009-03-26 2010-03-25 Nk细胞的扩增

Country Status (10)

Country Link
US (1) US8877182B2 (enExample)
EP (1) EP2411507B1 (enExample)
JP (3) JP2012521215A (enExample)
KR (1) KR101881520B1 (enExample)
CN (1) CN102428173B (enExample)
DK (1) DK2411507T3 (enExample)
ES (1) ES2763169T3 (enExample)
PL (1) PL2411507T3 (enExample)
PT (1) PT2411507T (enExample)
WO (1) WO2010110734A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2203176B1 (en) 2007-09-28 2014-11-26 Anthrogenesis Corporation Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
MX342995B (es) 2010-07-13 2016-10-21 Anthrogenesis Corp Métodos de generar células asesinas naturales.
JP5572863B2 (ja) 2011-06-24 2014-08-20 国立大学法人九州大学 Ｎｋ細胞の増幅方法
CN104204194B (zh) * 2011-12-22 2018-08-03 财团法人牧岩生命工学研究所 生产自然杀伤细胞的方法、由该方法生产的自然杀伤细胞以及包含该自然杀伤细胞的用于治疗癌症和感染性疾病的组合物
US10066207B2 (en) 2012-04-18 2018-09-04 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
KR101520534B1 (ko) 2012-05-07 2015-05-21 고려대학교 산학협력단 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
KR101525199B1 (ko) * 2012-09-13 2015-06-04 (주)케이셀바이오 100㎖ 이하 말초혈액으로부터 ｎｋ세포의 대량 증식 방법
CN102994449A (zh) * 2012-12-13 2013-03-27 上海柯莱逊生物技术有限公司 一种体外扩增nk细胞的方法
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
EP3622960A1 (en) 2013-02-05 2020-03-18 Celularity, Inc. Natural killer cells from placenta
US20160075996A1 (en) * 2013-03-27 2016-03-17 Biotherapy Institute Of Japan Method for producing nk cell-enriched blood preparation
US10260038B2 (en) 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
WO2015125113A1 (en) * 2014-02-21 2015-08-27 Dr. Reddy's Laboratories Limited Method of culturing high cell density pbmc's
CN105002139B (zh) * 2014-04-25 2019-02-01 中国医学科学院肿瘤医院 一种cd3+cd8+cd56+t细胞亚型促进nk细胞增殖的方法
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
CN104357390B (zh) * 2014-10-15 2017-07-07 恒瑞源正（深圳）生物科技有限公司 同时扩增cd3+cd56+cik细胞和cd3‑cd56+nk细胞的方法
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
US12098387B2 (en) 2015-10-19 2024-09-24 University Of Maryland, Baltimore Methods for generating engineered human primary blood dendritic cell lines
CN105624109B (zh) * 2016-02-26 2019-07-12 广州赛莱拉干细胞科技股份有限公司 一种使用生物反应器培养nkt细胞的方法
CN107779434A (zh) * 2016-08-30 2018-03-09 天津市康婷生物工程有限公司 高效扩增人外周血nk细胞的实验方法
AU2018219895C1 (en) 2017-02-09 2024-10-03 Indapta Therapeutics, Inc. Engineered Natural Killer (NK) cells and compositions and methods thereof
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
EP3633029A4 (en) 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
CN107541491A (zh) * 2017-10-12 2018-01-05 广州金晟生物科技有限公司 一种nk细胞体外培养方法
KR102265437B1 (ko) 2017-11-24 2021-06-15 의료법인 성광의료재단 Nk 배양용 조성물 및 이를 이용하여 nk 세포를 배양하는 방법
CN108060130B (zh) * 2017-12-29 2018-12-07 广州沙艾生物科技有限公司 控制培养箱适于免疫细胞的诱导扩增的方法
CN108192868B (zh) * 2017-12-29 2018-12-07 广州沙艾生物科技有限公司 免疫细胞的诱导扩增方法
CN115710576A (zh) 2018-02-01 2023-02-24 Nkmax有限公司 产生天然杀伤细胞的方法和用于治疗癌症的组合物
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
CN112513079A (zh) * 2018-03-13 2021-03-16 拉巴斯大学医院生物医学研究基金会 用于癌症免疫疗法的联合激活和扩增的自然杀伤细胞的抗cxcr4抗体
WO2019182392A1 (ko) * 2018-03-23 2019-09-26 주식회사 녹십자랩셀 자연살해세포의 제조방법
KR102232321B1 (ko) * 2018-03-23 2021-03-26 주식회사 녹십자랩셀 자연살해세포의 제조방법
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
GB201807050D0 (en) * 2018-04-30 2018-06-13 Cellprotect Nordic Pharmaceuticals Ab Medical uses
KR102069704B1 (ko) * 2018-05-16 2020-01-23 고려대학교 산학협력단 Hdac 억제제를 이용한 사람 유래 자연살해세포의 확장 배양법
EP3822341A4 (en) * 2018-05-31 2022-03-09 Korea University Research and Business Foundation EXPANSION AND CULTURE OF HUMAN-DERIVED NATURAL KILLER CELLS USING IGFBP2
CN110628715B (zh) * 2018-06-21 2022-11-25 精准生技股份有限公司 体外扩增自然杀手细胞及自然杀手t细胞的方法及其医药组成物
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
JP7179986B2 (ja) 2018-11-14 2022-11-29 グリーン クロス ラボ セル コーポレーション 形質転換されたｔ細胞を用いた臍帯血由来のナチュラルキラー細胞の培養方法
EP3884041A2 (en) 2018-11-21 2021-09-29 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
JP2022525928A (ja) * 2019-03-21 2022-05-20 ガミダ セル リミテッド 併用療法における移植に適したｎｋ細胞画分の増殖及び増殖ｎｋ細胞画分の使用
CN113166726A (zh) * 2019-07-08 2021-07-23 南克维斯特公司 单核细胞源性nk细胞
US11453862B2 (en) 2019-07-08 2022-09-27 Immunitybio, Inc. Mononuclear cell derived NK cells
WO2021154886A1 (en) 2020-01-28 2021-08-05 Sorrento Therapeutics, Inc. Natural killer cells for treatment of coronavirus infection
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
WO2022153295A1 (en) * 2021-01-12 2022-07-21 Hadasit Medical Research Services & Development Ltd. Improved adoptive cell transfer therapy for cancer
GB202115389D0 (en) 2021-10-26 2021-12-08 XNK Therapeutics AB Methods
WO2023081813A1 (en) 2021-11-05 2023-05-11 St. Jude Children's Research Hospital, Inc. Zip cytokine receptors
EP4536687A1 (en) 2022-06-08 2025-04-16 St. Jude Children's Research Hospital, Inc. Disruption of kdm4a in t cells to enhance immunotherapy
WO2024059787A1 (en) 2022-09-16 2024-03-21 St. Jude Children's Research Hospital, Inc. Disruption of asxl1 in t cells to enhance immunotherapy
WO2026156062A2 (en) 2025-01-15 2026-07-23 St. Jude Children's Research Hospital, Inc. Chimeric antigen receptors targeting cluster of differentiation 19 (cd19) and cluster of differentiation 22 (cd22)
WO2026165423A2 (en) 2025-01-31 2026-08-06 St. Jude Children's Research Hospital, Inc. Methods for enhancing immune effector cell activity leveraging biophysical modulation in adoptive cellular therapies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101005850A (zh) * 2004-06-18 2007-07-25 健泰科生物技术公司 使用apo2l受体激动剂和nk细胞活化剂的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2383418T3 (es) * 1999-11-24 2012-06-21 Red Cliff Holding Agente celular antiangiogénico para la terapia del cáncer.
US20030119185A1 (en) * 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
CN1444648A (zh) * 2000-06-06 2003-09-24 麒麟麦酒株式会社 扩增自然杀伤t细胞的方法
US20030068306A1 (en) * 2001-09-14 2003-04-10 Dilber Mehmet Sirac Medium
US20090196850A1 (en) * 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
KR101299299B1 (ko) * 2007-11-05 2013-08-26 츠네오 쿠라모치 암면역 요법용 세포의 제조방법
US20090123442A1 (en) * 2007-11-09 2009-05-14 Avaris Ab Expanded nk cells
KR20090127974A (ko) * 2008-06-10 2009-12-15 주식회사 엔케이바이오 자기활성화 림프구 배양용 배지 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101005850A (zh) * 2004-06-18 2007-07-25 健泰科生物技术公司 使用apo2l受体激动剂和nk细胞活化剂的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells;Stefan Carlens et al;《Human immunology》;20011231;第62卷(第10期);第1092页右栏摘要第1-5行、第1095页右栏第16-18行、第1092页左栏摘要第5-7行 *

Also Published As

Publication number Publication date
PT2411507T (pt) 2020-01-09
JP6574823B2 (ja) 2019-09-11
JP2018046840A (ja) 2018-03-29
CN102428173A (zh) 2012-04-25
HK1170258A1 (en) 2013-02-22
DK2411507T3 (da) 2020-01-06
EP2411507B1 (en) 2019-09-25
ES2763169T3 (es) 2020-05-27
EP2411507A1 (en) 2012-02-01
KR20110132618A (ko) 2011-12-08
KR101881520B1 (ko) 2018-07-24
US20120258085A1 (en) 2012-10-11
WO2010110734A1 (en) 2010-09-30
JP2012521215A (ja) 2012-09-13
EP2411507A4 (en) 2013-06-19
JP2016105713A (ja) 2016-06-16
PL2411507T3 (pl) 2020-07-13
US8877182B2 (en) 2014-11-04

Similar Documents

Publication Publication Date Title
JP6574823B2 (ja) Ｎｋ細胞の増殖
Lamers-Kok et al. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies
EP3344759B1 (en) Method for natural killer cell expansion
Fang et al. Advances in NK cell production
JP7557487B2 (ja) 幹細胞および／または前駆細胞からｔ前駆細胞を作製する方法ならびに該ｔ前駆細胞の使用
Klingemann Challenges of cancer therapy with natural killer cells
Sutlu et al. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor
CN103097520B (zh) 产生自然杀伤细胞的方法
Lupo et al. Differentiation of natural killer cells from induced pluripotent stem cells under defined, serum-and feeder-free conditions
KR101706524B1 (ko) 안정성 높은 자연살해세포의 효율적인 제조방법
JP6073417B2 (ja) 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
JP2006525013A (ja) 血液幹細胞の数の増幅のための装置および方法
US20250354116A1 (en) Method for enhancing production of genetically engineered autologous t cells
Davis et al. Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation
WO2020260875A1 (en) Culture medium
TW202117008A (zh) 細胞激素誘導記憶型自然殺手細胞及其方法
US20240117309A1 (en) Methods for expanding t cell populations
US20250313804A1 (en) Methods for expanding natural killer cells (nk cells)
HK1170258B (en) Expansion of nk cells
Class et al. Patent application title: METHOD FOR NATURAL KILLER CELL EXPANSION

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: CELL MAINTENANCE NORTHERN EUROPE PHARMACEUTICAL CO

Free format text: FORMER OWNER: AVARIS LTD.

Effective date: 20121225

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20121225

Address after: Stockholm

Applicant after: AVARIS AB

Address before: Hu Dinge, Sweden

Applicant before: Avaris AB

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1170258

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1170258

Country of ref document: HK